Last reviewed · How we verify
NCT06696326
A Multicenter Study Evaluating the Diagnostic Value of 68Ga-MY6349 PET/CT for Prostate Cancer
NA trial testing standard-of-care imaging 68Ga-MY6349 and 68Ga-PSMA-11 in Positron-Emission Tomography(PET) in 100 participants. Currently enrolling.
15 October 2025
Quick facts
| Lead sponsor | The First Affiliated Hospital of Xiamen University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 100 |
| Start date | 1 October 2024 |
| Primary completion | 15 October 2025 |
| Estimated completion | 15 October 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- standard-of-care imaging 68Ga-MY6349 and 68Ga-PSMA-11
Conditions studied
- Positron-Emission Tomography(PET) — all drugs for Positron-Emission Tomography(PET) →
- Prostate Cancer — all drugs for Prostate Cancer →
- Trophoblast Cell Surface Antigen 2 — all drugs for Trophoblast Cell Surface Antigen 2 →
Sponsor
The First Affiliated Hospital of Xiamen University
Who can join
Adults 18 to 90, male only, with Positron-Emission Tomography(PET) or Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main objective of this research is to develop and evaluate new PET imaging agents with high sensitivity and specificity for prostate cancer and other aggressive tumors. Specifically, the research focuses on improving upon existing prostate cancer imaging methods, such as PSA tests and PSMA PET/CT, which have limitations in sensitivity, specificity, and the ability to provide comprehensive tumor information，and aims to create a novel PET probe targeting Trop2, an antigen highly expressed in multiple cancer types, to enable in vivo, whole-tumor assessment. This would support early diagnosis, more precise staging, and effective monitoring of cancer therapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06696326
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other The First Affiliated Hospital of Xiamen University trials
Trials by the same sponsor.
- NCT06875063 — GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL · Phase 1 · recruiting
- NCT07486492 — Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer · EARLY_PHASE1 · not yet recruiting
- NCT07458906 — DLL3-Targeted PET/CT in Neuroendocrine Carcinoma · NA · recruiting
- NCT07137052 — Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinomar · not yet recruiting
- NCT07189884 — Pyrotinib Maleate Tablets in Combination With Dalpiciclib Isethionate Tablets and Standard Endocrine Therapy · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06696326 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Xiamen University
- Last refreshed: 18 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06696326.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing